We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Flagship seeds Sigilon with $23.5mm to develop Type I diabetes therapy
06 Apr 2018
Executive Summary
Flagship Pioneering launched Sigilon Therapeutics Inc. and seeded the company with $23.5mm. The start-up, armed with the research of its co-founders Daniel Anderson, PhD, and Robert Langer (both from MIT), is using an alginate-based polymeric capsule to encapsulate allogeneic cells that have been engineered into insulin-producing pancreatic beta cells. The company believes that its technology will avoid tissue scarring and immune responses that would other destroy implanted cells before they can be effective as a treatment for Type I diabetes.
Deal Industry
Pharmaceuticals
Biotechnology
Gene Therapy, Cell Therapy
Large Molecule
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?